Stockholm Medical Cannabis Conference

Three Phytocannabinoids Join Forces to Battle NOTCH1-Mutated T-Cell Lymphoblastic Acute Leukemia

Investigating the synergistic effects of cannabinoids 331-18A, CBDV, and CBD, this groundbreaking study targets NOTCH1-Mutated T-Cell Lymphoblastic Acute Leukemia (T-ALL) through the Integrated Stress Response Pathway. By exploring the ‘entourage effect’ with a combination of specific phytocannabinoids, the research opens up new therapeutic horizons, shedding light on the intricate molecular interactions and their potential in cancer treatment.

Improving cannabinoid posology through nanotechnology

This article explores the role of nanotechnology in improving the delivery and efficacy of cannabinoids. By focusing on nanoencapsulation techniques such as liposomes and polymeric nanoparticles, we delve into how these methods can enhance bioavailability, stability, and therapeutic efficacy of cannabinoids, thereby offering significant advancements in molecular pharmacology.

Synuclein Synchrony: A Dance of Proteins and Endocannabinoids in Parkinson’s Disease

In the groundbreaking study “Postsynaptic Synucleins Mediate Endocannabinoid Signaling,” Eddy Albarran and colleagues delve into the intricate dance between synucleins and endocannabinoids within postsynaptic neurons. Their findings shed light on the potential role of phytocannabinoids in alleviating symptoms of Parkinson’s disease, offering a fresh perspective on therapeutic strategies

In Memoriam – Dr. Raphael Mechoulam

Celebrating the life and legacy of Dr. Raphael Mechoulam, a pioneering scientist in the fields of molecular pharmacology and cannabinoid research. His groundbreaking work on the endocannabinoid system (ECS) has transformed our understanding of human physiology and medical science.